RALEIGH, N.C., Jan. 16 /PRNewswire/ -- Voyager Pharmaceutical Corporation, the specialty pharmaceutical company focused on diseases of aging and development, announced Monday that Dr. Joseph DeVeaugh-Geiss will act as interim Chief Medical Officer. DeVeaugh-Geiss has played a significant role with Voyager for more than three years. He has been directly involved in the design and oversight of the Phase I study, along with the Phase II and Phase III double-blind, placebo-controlled trials (ALADDIN) investigating the safety and effectiveness of leuprolide acetate as a potential treatment for Alzheimer’s disease.
“Since 2002, Joe’s leadership role has been invaluable to Voyager. His guidance related to drug development plans has been a key to our clinical success,” said Patrick Smith, the company’s president and CEO. “I’m glad that we can draw from Joe’s extraordinary experience with the design, execution and analysis of clinical research activities.” DeVeaugh-Geiss spent more than 16 years in the pharmaceutical industry with CIBA-GEIGY and Glaxo/Glaxo Wellcome/GlaxoSmithKline. During that time, he contributed to and managed the successful submission of more than 12 New Drug Applications (NDAs) and Supplemental New Drug Applications (sNDAs).
“I am honored to assume this added responsibility,” said DeVeaugh-Geiss. “Voyager has a strong platform of research, and I am optimistic that Phase II results will be reinforced by the data obtained from the company’s Phase III pivotal studies.”
DeVeaugh-Geiss serves as an independent consultant and founder of BRAINSTORM CNS, LLC. In that role, he provides consulting services to biotechnology and pharmaceutical companies, as well as governmental agencies in the areas of drug development and central nervous system research. He draws upon his experience both in academia and in the pharmaceutical industry. Most recently, he was Vice President and International Director of Central Nervous System Clinical Research for Glaxo Wellcome/GlaxoSmithKline. He maintains academic appointments at the Duke University Medical Center, Duke Clinical Research Institute, University of North Carolina at Chapel Hill, State University of New York (SUNY) Health Science Center and the American University of the Caribbean.
About Voyager Pharmaceutical Corporation
Voyager Pharmaceutical Corporation is a biopharmaceutical company focused on developing drugs for diseases associated with aging and development. Voyager’s scientific approach is based on the observation that many diseases of aging may be caused by changes in human reproductive hormone levels that are characteristic of the aging process. Voyager’s most advanced product candidate is Memryte, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer, that is currently in phase III clinical studies ( the ALADDIN studies) for the treatment of mild to moderate
Alzheimer’s disease. Voyager was founded in 2001 and is headquartered in Raleigh, N.C.
Contact Information:
Patrick S. Smith, President and CEO
919-846-4880
Voyager Pharmaceutical Corporation
CONTACT: Patrick S. Smith, President and CEO of Voyager PharmaceuticalCorporation, 919-846-4880
